Glucose-6-phosphate dehydrogenase deficiency and Alzheimer's disease: Partners in crime? The hypothesis

Medical Hypotheses

Volumn 85, Issue 2, 2015, Pages 219-223

  Ulusu, N Nuray ^a  

^a KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; DISEASE ASSOCIATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; INBORN ERROR OF METABOLISM; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; BIOLOGICAL MODEL; BRAIN; COMPLICATION; METABOLISM;

ALZHEIMER DISEASE; BRAIN; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES;

EID: 84942824320     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.05.006     Document Type: Article

References (81)

1. Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, et al. Targets for AD treatment: conflicting messages from c-secretase inhibitors. J Neurochem 2011;117:359-74.
2. Fändrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer's β-amyloid structures. Trends Biochem Sci 2011;36:338-45.
3. Yu QS, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, et al. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products [+]-N1-norPosiphen, [+]-N8-norPosiphen and [+]-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, a-Synuclein synthesis, interleukin-1b release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem 2013;12:117-28.
4. Shin RW, Ogomori K, Kitamoto T, Tateishi J. Increased tau accumulation in senile plaques as a hallmark in Alzheimer's disease. Am J Pathol 1989;134:1365-71.
5. Yu J, Gattoni-Celli M, Zhu H, Bhat NR, Sambamurti K, Gattoni-Celli S, et al. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AbPP transgenic mice. J Alzheimers Dis 2011;25:295-307.
6. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368: 387-403.
7. Noble W, Pooler AM, Hanger DP. Advances in tau-based drug discovery. Expert Opin Drug Discov 2011;6:797-810.
8. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
9. Ryan NS, Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med 2010;1:99-112.
10. Miyoshi K. What is 'early onset dementia'? Psychogeriatrics 2009;9:67-72.
11. Jiyoung P, Ho Kyung R, Kang Ho K, Sung Sik C, Yun Sok L, Jae Bum K. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol 2005;25:5146-57.
12. Ulusu NN, Tandogan B. Purification and kinetics of sheep kidney cortex glucose-6-phosphate dehydrogenase. Comp Biochem Physiol B Biochem Mol Biol 2006;143:249-55.
13. Cheung CY, Ong YT, Ikram MK, Ong SY, Li X, Hilal S, et al. Microvascular network alterations in the retina of patients with Alzheimer's disease. Alzheimers Dement 2014;10:135-42.
14. Dogru Pekiner B, Daş Evcimen N, Ulusu NN, Bali M, Karasu C. Effects of vitamin E on microsomal Ca[2+]-ATPase activity and calcium levels in streptozotocininduced diabetic rat kidney. Cell Biochem Funct 2003;21:177-82.
15. Das Evcimen N, Ulusu NN, Karasu C, Doğru B. Adenosine triphosphatase activity of streptozotocin-induced diabetic rat brain microsomes. Effect of vitamin E. Gen Physiol Biophys 2004;23:347-55.
16. Ulusu NN, Turan B. Beneficial effects of selenium on some enzymes of diabetic rat heart. Biol Trace Elem Res 2005;103:207-16.
17. Can B, Ulusu NN, Kilinç K, Leyla Acan N, Saran Y, Turan B. Selenium treatment protects diabetes-induced biochemical and ultrastructural alterations in liver tissue. Biol Trace Elem Res 2005;105:135-50.
18. Tuncay E, Seymen AA, Tanriverdi E, Yaras N, Tandogan B, Ulusu NN, et al. Gender related differential effects of omega-3E treatment on diabetes-induced left ventricular dysfunction. Mol Cell Biochem 2007;304:255-63.
19. Ozdemir S, Tandogan B, Ulusu NN, Turan B. Angiotensin II receptor blockage prevents diabetes-induced oxidative damage in rat heart. Folia Biol [Praha] 2009;55:11-6.
20. Pekiner B, Ulusu NN, Das-Evcimen N, Sahilli M, Aktan F, Stefek M, et al. In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+-ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E. Antioxidants in Diabetes-Induced Complications Study Group. Biochim Biophys Acta 2002;1588:71-8.
21. Ulusu NN, Sahilli M, Avci A, Canbolat O, Ozansoy G, Ari N, et al. Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defense during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E. Neurochem Res 2003;28:815-23.
22. Selvatici R, Marani L, Marino S, Siniscalchi A. In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease. Neurochem Int 2013;63:112-20.
23. Tandogan B, Ulusu NN. Comparative in vitro effects of some metal ions on bovine kidney cortex glutathione reductase. Prep Biochem Biotechnol 2010;40:405-11.
24. Maloney B, Sambamurti K, Zawia N, Lahiri DK. Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation [LEARn] model. Curr Alzheimer Res 2012;9:589-99.
25. Katzman R. Alzheimer's disease. N Engl J Med 1986;314:964-73.
26. Sochocka M, Koutsouraki ES, Gasiorowski K, Leszek J. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: a new approach to therapy. CNS Neurol Disord Drug Targets 2013;12: 870-81.
27. Sagy-Bross C, Hadad N, Levy R. Cytosolic phospholipase A2a upregulation mediates apoptotic neuronal death induced by aggregated amyloid-b peptide 1-42. Neurochem Int 2013;63:541-50.
28. Berg L, McKeel Jr DW, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-35.
29. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004;140:627-38.
30. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010;10:14946-54.
31. Maccioni RB, Muñoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001;32:367-81.
32. Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem 2013;288:1295-306.
33. Medina M, Avila J. New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. Expert Opin Ther Targets 2014;18:69-77.
34. Anand P, Singh B. Flavonoids as lead compounds modulating the enzyme targets in Alzheimer's disease. Med Chem Res 2013;22:3061-75.
35. Wang W, Liu Y, Lazarus RA. Allosteric inhibition of BACE1 by an exositebinding antibody. Curr Opin Struct Biol 2013;23:797-805.
36. Tan J, Evin G. β-Site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis. J Neurochem 2012;120:869-80.
37. Deng Y, Wang Z, Wang R, Zhang X, Zhang S, Wu Y, et al. Amyloid-b protein [Ab] Glu11 is the major β-secretase site of b-site amyloid-b precursor proteincleaving enzyme 1[BACE1], and shifting the cleavage site to Ab Asp1 contributes to Alzheimer pathogenesis. Eur J Neurosci 2013;37:1962-9.
38. Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, et al. Targets for AD treatment: conflicting messages from c-secretase inhibitors. Neurochemistry 2011;117:359-74.
39. Aoki M, Yokota T, Sugiura I, Sasaki C, Hasegawa T, Okumura C, et al. Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 beta. Acta Crystallogr D Biol Crystallogr 2004;60:439-46.
40. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 2008;172:1342-54.
41. Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, Francis YI, et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. Eur J Med Chem 2013;60:285-94.
42. Kv Lu'o'ng, Nguyen LT. Role of thiamine in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011;26:588-98.
43. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23: 795-807.
44. Völkel W, Sicilia T, Pähler A, Gsell W, Tatschner T, Jellinger K, et al. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Intern 2006;48:679-86.
45. Ondei LS, Silveira LM, Leite AA, Souza DR, Pinhel MA, Percário S, et al. Lipid peroxidation and antioxidant capacity of G6PD-deficient patients with A-[202G>A] mutation. Genet Mol Res 2009;10:1345-51.
46. Vidoni ED, Van Sciver A, Johnson DK, He J, Honea R, Haines B, et al. A community-based approach to trials of aerobic exercise in aging and Alzheimer's disease. Contemp Clin Trials 2012;33:1105-16.
47. Richardson JR, Roy A, Shalat SL, von Stein RT, Hossain MM, Buckley B, et al. Elevated serum pesticide levels and risk for Alzheimer disease. JAMA Neurol 2014;71:284-90.
48. Dias IH, Polidori MC, Li L, Weber D, Stahl W, Nelles G, et al. Plasma levels of HDL and carotenoids are lower in dementia patients with vascular comorbidities. J Alzheimers Dis 2014;40:399-408.
49. Camargos EF, Louzada FM, Nóbrega OT. Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness, and challenges. Sleep Med Rev 2013;17:475-88.
50. Debette S, Wolf C, Lambert JC, Crivello F, Soumaré A, Zhu YC, et al. Abdominal obesity and lower gray matter volume: a Mendelian randomization study. Neurobiol Aging 2014;35:378-86.
51. Armstrong RA. What causes Alzheimer's disease? Folia Neuropathol 2013;51:169-88.
52. Patrinostro X, Carter ML, Kramer AC, Lund TC. A model of glucose-6-phosphate dehydrogenase deficiency in the zebrafish. Exp Hematol 2013;41:697-710.
53. Berg JM, Tymoczko JL, Stryer L. Biochemistry. United States of America: W.H. Freeman and Company; 2002.
54. Xie HB, Cammarato A, Rajasekaran NS, Zhang H, Suggs JA, Lin HC, et al. The NADPH metabolic network regulates human aB-crystallin cardiomyopathy and reductive stress in Drosophila melanogaster. PLoS Genet 2013;9:1-14.
55. Scotti L, Mendonca FJB, da Silva MS, Pitta IR, Scotti MT. Biochemical changes evidenced in Alzheimer's disease: a mini-review. Lett Drug Des Discov 2014;11:240-8.
56. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 1999;370:236-9.
57. Rahman K. Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging 2007;2:219-36.
58. Wirz KTS, Keitel S, Swaab DF, Verhaagen J, Bossers K. Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase? J Alzheimers Dis 2014;38:719-40 [Review].
59. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-67.
60. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, et al. NADPH-oxidasederived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 2005;16:1769-77.
61. Navarro-Yepes J, Zavala-Flores L, Anandhan A, Wang F, Skotak M, Chandra N, et al. Antioxidant gene therapy against neuronal cell death. Pharmacol Ther 2014;142:206-30.
62. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 2012;64:362-9.
63. Song YL, Kenworthy AK, Sanders CR. Cholesterol as a co-solvent and a ligand for membrane proteins. Protein Sci 2014;23:1-22.
64. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004;3:171-87.
65. Guz G, Demirogullari B, Ulusu NN, Dogu C, Demirtola A, Kavutcu M, et al. Stobadine protects rat kidney against ischaemia/reperfusion injury. Clin Exp Pharmacol Physiol 2007;34:210-6.
66. Dogru Pekiner B, Daş Evcimen N, Ulusu NN, Bali M, Karasu C. Effects of vitamin E on microsomal Ca[2+]-ATPase activity and calcium levels in streptozotocininduced diabetic rat kidney. Cell Biochem Funct 2003;21:177-82.
67. Pekiner B, Ulusu NN, Das-Evcimen N, Sahilli M, Aktan F, Stefek M, et al. In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+-ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E. Biochim Biophys Acta 2002;9:71-8.
68. Demirer S, Ulusu NN, Aslim B, Kepenekci I, Ulusoy C, Andrieu MN, et al. Protective effects of Lactobacillus delbrueckii subsp. bulgaricus B3 on intestinal enzyme activities after abdominal irradiation in rats. Nutr Res 2007;27:300-5.
69. Brown DI, Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med 2009;47:1239-53.
70. Hernandes MS, Britto LR. NADPH oxidase and neurodegeneration. Curr Neuropharmacol 2012;10:321-7.
71. Whiley L, Sen A, Heaton J, Proitsi P, García-Gómez D, Leung R, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 2014;35:271-8.
72. Jeng W, Loniewska MM, Wells PG. Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. ACS Chem Neurosci 2013;17:1123-32.
73. Mavroudis IA, Manani MG, Petrides F, Petsoglou K, Njau SD, Costa VG, et al. Dendritic and spinal pathology of the Purkinje cells from the human cerebellar vermis in Alzheimer's disease. Psychiatr Danub 2013;25:221-6.
74. Wang Q, Xiao B, Cui S, Song H, Qian Y, Dong L, et al. Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis Model Mech 2014;7:1385-95.
75. Hensley K, Harris-White ME. Redox regulation of autophagy in healthy brain and neurodegeneration. Neurobiol Dis Mar 2015; 11. pii: S0969-9961(15)00063-7. doi:http://dx.doi.org/10.1016/j.nbd.2015.03.002.
76. Huang HC, Tang D, Lu SY, Jiang ZF. Endoplasmic reticulum stress as a novel neuronal mediator in Alzheimer's disease. Neurol Res 2015;37:366-74.
77. Száraz P, Bánhegyi G, Benedetti A. Altered redox state of luminal pyridine nucleotides facilitates the sensitivity towards oxidative injury and leads to endoplasmic reticulum stress dependent autophagy in HepG2 cells. Int J Biochem Cell Biol J 2010;42:157-66.
78. Lavery GG, Walker EA, Turan N, Rogoff D, Ryder JW, Shelton JM, et al. Deletion of hexose-6-phosphate dehydrogenase activates the unfolded protein response pathway and induces skeletal myopathy. J Biol Chem 2008;283:8453-61.
79. Zielinska AE, Walker EA, Stewart PM, Lavery GG. Biochemistry and physiology of hexose-6-phosphate knockout mice. Mol Cell Endocrinol 2011;10:213-8.
80. Senesi S, Csala M, Marcolongo P, Fulceri R, Mandl J, Banhegyi G, et al. Hexose-6-phosphate dehydrogenase in the endoplasmic reticulum. Biol Chem 2010;391:1-8.
81. Abdel Moneim AE. Oxidant/antioxidant imbalance and the risk of Alzheimer's disease. Curr Alzheimer Res 2015 [Epub ahead of print].